Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.
about
Secondary treatment of acute graft-versus-host disease: a critical reviewTreatment of chronic graft-versus-host disease in 2011Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan.Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation.Recent advances in the management of graft-versus-host disease.Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.Treatment of chronic graft-versus-host disease: Past, present and future.First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.Clinical benefit of response in chronic graft-versus-host diseasePharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyNonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantationAdvances in the treatment of acute graft-versus-host disease.Treatment and management of graft-versus-host disease: improving response and survival.Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies.State-of-the-art acute and chronic GVHD treatment.Insurance approval of mesenchymal stem cell for acute GVHD in Japan: need of follow up for some remaining concerns.Acute and chronic Graft-versus-host disease after hematopoietic stem cell transplantation.Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation.Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome.Expression of CD30 in patients with acute graft-versus-host diseaseMycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan.Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.New and emerging therapies for acute and chronic graft versus host disease.Regional intra-arterial steroid treatment in 120 patients with steroid-resistant or -dependent GvHD.National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.Pulmonary Allograft Versus Host Disease.
P2860
Q26823275-718CA4B6-ECED-4FFE-9D58-22FFEEBFAA1AQ26851433-26EFAAE4-5048-4D0A-BD55-4EC54C7AFB82Q33394786-D282C1FA-4E23-46BE-8E6E-72A2FB29F22BQ33411063-58D97DE8-0A5F-4D0D-9331-9F7725C32AC6Q34428890-8A633464-0E61-40A3-BF50-44A237A28CD8Q35140097-4DDFBC06-A47A-478D-8BDF-6481D35BC8E3Q35524687-531EB64C-FAB8-42C4-8D45-25637ADD3390Q36113205-0B341E4F-97E3-4149-AED8-31CC26AE9093Q36236504-D97626A0-E7EA-452B-9F32-E1DB80781AA0Q36777485-81A4EAA3-0872-4F47-AB94-023FC2863FA3Q36862931-AD1AE4E3-F618-42B2-8A7C-9D05DD7D758EQ37038889-096F2D85-8240-4756-BC74-75EECE4D0B22Q37191057-A3F6BF25-EAC0-4436-B34B-3CB88FCF0370Q37371836-4C457A00-61C8-4C7F-A88A-A052844DEEF4Q38010596-7D93CA4E-9C45-4891-A681-48E3F31FFC8DQ38226527-A95E26EE-EF90-4E16-933B-9181554C500FQ38416376-55D3AC1C-88C7-4087-A099-C267DE909587Q38694213-A064B427-926C-421D-ACB0-0A07D5454717Q39041077-6C1D0400-D9AB-4CDB-9BD2-760B472488EEQ41144188-BF35A833-7299-4AE8-A8CE-1D1F1AF1F050Q41290373-B605A774-06C2-49D8-9765-87E75068A232Q41984840-74078D33-24C6-40F2-8AF9-F7C35A04DDFDQ43522314-15EAF04B-F03F-4BCA-8A11-5D7A9AE40876Q48362201-2F2D475B-07A3-46AE-BB57-ACEEBE421FB2Q49238507-5AB592FF-11F1-45BF-8914-2284625412C0Q50561008-85BC33F1-315B-4CBC-9A14-EE6FDC353FE5Q50861552-832EA876-B80D-4DB8-865B-8131812D3E03Q54256405-16E71DC8-F234-448E-82DB-AEE3EFFA0327
P2860
Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.
@en
Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.
@nl
type
label
Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.
@en
Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.
@nl
prefLabel
Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.
@en
Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.
@nl
P2093
P2860
P50
P356
P1476
Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.
@en
P2093
F Carnevale-Schianca
K M Sullivan
M E D Flowers
R Witherspoon
R Yatscoff
T Chauncey
P2860
P2888
P304
P356
10.1038/BMT.2009.76
P407
P577
2009-04-20T00:00:00Z